Targesome, Inc.

Other

Leland Stanford Junior University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

King Chuen Li

Mark David Bednarski

Jeremy Kenji Kuniyoshi

Henry Y Li

Dorothy Anna Sipkins

Francois Daniel Tropper

Richard Wood Storrs

Curtis Kang Song

Peter G Ang

Samira Guccione

Curtis Kang Hoon Song

S Narasimhan Danthi

Christopher A Burnett

Francois D Trooper

The in vivo delivery of nucleic acids is targeted by delivery of the nucleic acid in a complex with cross-linked nanoparticles; where the nanoparticles comprise cross-linked neutral amphipathic molecules, cationic amphipathic molecules and targeting amphipathic molecules. Optionally the cationic and targeting amphipathic molecules are also cross-linked. A targeting moiety present on the targeting amphipathic molecule provides for selective delivery of the complex to a predetermined target site, e.g. blood vessels, endothelial cells, tumor cells, liver cells, and the like.

Targeted cross-linked nanoparticles and their use in vivo gene delivery

A tissue is imaged to detect the presence of amyloid deposits or other target proteins prior to their aggregation into plaques, with the assistance of the administration of a labeled bifunctional compound of which one functionality binds to the target protein and the second functionality binds to a chaperone protein that is present in the tissue of interest. The two functionalities have different binding affinities, the target-binding functionality having the greater binding affinity, with the result that the bifunctional compound preferentially remains in the tissue when bound to the chaperone and then the target protein while bifunctional compound that is not bound to the target protein will leave the tissue. The inclusion of the chaperone allows the imaging process to detect the non-aggregated proteins by way of the label and the difference in kinetics of the binding to the chaperone and the target protein permits one to distinguish between binding of the bifunctional molecule to the chaperone only and binding to the chaperone and then to the target protein. Certain intermediates toward the synthesis of these bifunctional compounds are novel by themselves, and labeled bifunctional molecules in general that utilize a lysine linker are also disclosed as a novel class of compounds.

Small molecules for imaging protein-protein interactions

Use of targeted cross-linked nanoparticles for in vivo gene delivery

Integrin receptor antagonists whose molecular structure includes a tetrahydropyridimidinylaminoethyloxybenzoyl group on a sulfonylamino-&#x3b2;-alanine nucleus exhibit increased binding affinity for the &#x3b1;v&#x3b2;3 receptor when further substituted on the sulfonyl moiety with an N-amino alkycarbamyl group or a butyloxycarbonylamino alkylcarbamoyl group or similar groups.

Integrin &#x3b1;-v &#x3b2;-3 antagonists for use in imaging and therapy

Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.

Targeted polymerized liposome diagnostic and treatment agents

Use of polymerized lipid diagnostic agents

Targeted tissue in vivo is altered using focused energy to specifically control endothelial permeability and interstitial integrity. Image guidance may be used in combination with physical energy deposition to facilitate the targeted delivery of materials. The method of the invention serves as a platform for delivering pharmaceutical agents, nucleic acids, proteins, liposomes, etc. to cells.

Enhancement of bioavailability by use of focused energy delivery to a

Polymerized liposome particles based upon lipids having a polymerizable functional group and a metal chelator to attach an imaging enhancement agent and lipids having an active targeting group to provide targeted polymerized liposome contrast agents. The polymerized imaging enhancement liposome particles interact with receptor targets holding the image enhancement agent to specific sites providing in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology.

Targeted polymerized liposome contrast agents

A paramagnetic oil emulsion for magnetic resonance imaging composed of about 5 to about 30 volume percent oil and about 70 to about 95 volume percent aqueous-based paramagnetic agent carrier, at least one of the aqueous-based paramagnetic agent carrier and the oil having dissolved therein a magnetic resonance image contrast effective and less than a toxic amount of at least one soluble paramagnetic agent. The paramagnetic oil emulsion provides high intensity magnetic resonance signals in the gastrointestinal tract for MRI evaluation of the abdomen and pelvis, particularly in the distal bowel regions.

Paramagnetic oil emulsions as MRI contrast agents

A paramagnetic oil emulsion for enteric administration composed of about 5 to about 30 volume percent oil and about 70 to about 95 volume percent aqueous-based paramagnetic carrier, the aqueous-based paramagnetic carrier having a magnetic resonance contrast effective and less than a toxic amount of at least one water-soluble paramagnetic agent. The paramagetic oil emulsion provides high intensity magnetic resonance signals in the gastro-intestional tract for MRI evaluation of the abdomen and pelvis.

Growing community of inventors

Bethesda, MD, United States of America

King Chuen Li